Over the last 2 years there have been dramatic advances in the treatment of HIV infection. The availability of protease inhibitors and non-nucleoside reverse transcriptase inhibitors allowed the development of combinations of antiretroviral drugs (HAART) that can completely block HIV viral replication. The use of highly active antiretroviral therapy has dramatically changed the morbidity and mortality rates of HIV infection and AIDS. This progress is not without problems. Protease inhibitors have major toxicities that are only partially understood. They are difficult to take requiring tight schedules and dietary restrictions and they are expensive. Better strategies in the use of these drugs are needed in order to maximize clinical benefits and improve the quality of life of patients. Given the fact that large strategic trials of many different combinations are not feasible, it is essential to determine if alternative strategic approaches can be developed. Two possible options constitute the proposed research in this grant: a)the use of statistical methods such as decision analysis to guide treatment decisions, and b) use of small pilot studies to provide basis for supporting or rejecting hypothesis that can guide strategic decisions. To accomplish these aims the investigator will: 1) Perfrom computing modeling of different strategies in the management of antiretroviral therapy in HIV infected patients using decision analysis techniques as well as Markov models; 2) Evaluate whether a fully suppressive antiretroviral regimen containing a protease inhibitor can be simplified substituting the protease inhibitor with a non-nucleoside reverse transcriptase inhibitor (NNRTI). He will also determine whether this simplification strategy has additional pathophysiologic effects correcting the metabolic abnormalities associated with protease inhibitor therapy, changing the body composition of the patients as measured by DEXA (dual energy x-ray absorptiometry) scans, or changing the distribution and absolute numbers of CD4/CD8 T memory and na?ve cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23AI001612-02
Application #
6168751
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Program Officer
Sager, Polly R
Project Start
1999-04-15
Project End
2002-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
2
Fiscal Year
2000
Total Cost
$113,963
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Fredlake, Christopher P; Hert, Daniel G; Kan, Cheuk-Wai et al. (2008) Ultrafast DNA sequencing on a microchip by a hybrid separation mechanism that gives 600 bases in 6.5 minutes. Proc Natl Acad Sci U S A 105:476-81
Mondy, Kristin; Powderly, William G; Claxton, Sherry A et al. (2005) Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 38:426-31
Tebas, Pablo; Yarasheski, Kevin; Henry, Keith et al. (2004) Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 20:589-94
Uhlmann, Erik J; Tebas, Pablo; Storch, Gregory A et al. (2004) Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. J Clin Virol 31:198-203
Mondy, Kristin; Yarasheski, Kevin; Powderly, William G et al. (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482-90
Ristig, M B; Arens, M Q; Kennedy, M et al. (2002) Increasing prevalence of resistance mutations in antiretroviral-naive individuals with established HIV-1 infection from 1996-2001 in St. Louis. HIV Clin Trials 3:155-60
Ristig, Maria B; Crippin, Jeffrey; Aberg, Judith A et al. (2002) Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 186:1844-7
Tebas, P; Henry, K; Nease, R et al. (2001) Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. AIDS 15:591-9
Tebas, P; Powderly, W G (2000) Nelfinavir mesylate. Expert Opin Pharmacother 1:1429-40
Berman, M A; Nalesnik, M A; Kapadia, S B et al. (1986) Primary lymphadenopathic Kaposi's sarcoma in an immunocompetent 23-year-old man. Am J Clin Pathol 86:366-9